Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Yoo, HK; Byun, HG; Caprioli, F; Fumery, M; Peyrin-Biroulet, L; Sreedhar, S; Potter, J; Jang, M

Jang, M (通讯作者)，Celltrion Healthcare, 19,Acad Ro 51, Incheon, South Korea.

BMC HEALTH SERVICES RESEARCH, 2022; 22 (1):

Abstract

Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索